(2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2H-pyridine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2H-pyridine-1-carboxylate
• 化学式: C₁₈H₁₈N₂O₄S₂
• 分子量: 390.5
• InChiKey: UFIVODCEJLHUTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  118
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• Anti-EGFR antibodies and antibody drug conjugates
  申请人：AbbVie Inc.

  公开号：US10098968B2

  公开（公告）日：2018-10-16

  The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  本发明涉及抗表皮生长因子（EGFR）抗体和抗体药物共轭物（ADC），包括使用所述抗体和 ADC 的组合物和方法。
• Prolactin receptor binding proteins and uses thereof
  申请人：AbbVie Inc.

  公开号：US10184003B2

  公开（公告）日：2019-01-22

  The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

  本发明包括 PRLR 结合蛋白。具体来说，本发明涉及嵌合抗体、CDR 接枝抗体和人源化抗体。优选的抗体对 hPRLR 具有高亲和力，并能在体外和体内中和 hPRLR 的活性。本发明的抗体可以是全长抗体或其抗原结合部分。本发明还提供了抗体的制造方法和使用方法。本发明的抗体或抗体部分可用于检测 hPRLR 和抑制 hPRLR 活性，例如，在患有 hPRLR 活性有害的疾病的人体中。本发明还包括抗PRLR抗体药物共轭物（ADC）。
• Eribulin-based antibody-drug conjugates and methods of use
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US10322192B2

  公开（公告）日：2019-06-18

  Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

  本发明公开了与人类肿瘤抗原靶点（如叶酸受体α）结合和/或具有抗微管蛋白药物活性的连接体毒素和抗体-药物共轭物。 连接体毒素和抗体-药物共轭物由艾瑞布林药物分子组成，可以内化到靶抗原表达细胞中。 本公开进一步涉及通过施用本文提供的抗体-药物共轭物治疗癌症的方法和组合物。
• Anti-B7-H3 antibodies and antibody drug conjugates
  申请人：AbbVie Inc.

  公开号：US10640563B2

  公开（公告）日：2020-05-05

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  本发明涉及 B7 同源 3 蛋白（B7-H3）抗体和抗体药物共轭物（ADC），包括使用所述抗体和 ADC 的组合物和方法。